Ireland
--:--IST
Latest
Clinical Trials in the Netherlands / NCT06058351
Recruiting Not applicable

ABI-aftercare in Motion: Multidisciplinary Aftercare in the Home Environment in Patients With Acquired Brain Injury

NCT06058351 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Majanka H. Heijenbrok-Kal, PhD
Phase
Not applicable
Started
2024-03-01
Last updated
2025-08-29

Condition(s) studied

Acquired Brain Injury

Investigational drug(s) / intervention(s)

ABI-motion program

ABI-motion program: The ABI-motion program strengthens the cooperation between outpatient rehabilitation professionals and community care providers.

Study summary

The goal of this implementation study is to improve aftercare for patients with ABI receiving outpatient rehabilitation. The ABI-motion program was developed to improve and active lifestyle and to prevent persistent complaints after ABI and poor HR-QoL.The main questions it aims to answer are:

* Is the ABI-motion program feasible?
* What are the health benefits of the ABI-motion program?

Participants will receive brain education, a joint therapy session with a physical or occupational or movement therapist and a buddy from a patient support organization during outpatient rehabilitation, followed by community buddy support after discharge from outpatient rehabilitation, and follow-up by a rehabilitation physician.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosed with ABI * Follows an outpatient rehabilitation program for ABI in Rijndam Rehabilitation Exclusion Criteria: * Having a contra-indication for participation in moderate to vigorous exercise * Life expectancy \< 1 year * Incapacitated persons

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Rijndam Rehabilitation Rotterdam Netherlands Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06058351 on ClinicalTrials.gov ↗ ← All trials in the Netherlands